Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06544577
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-05
Brief Title:
Safety of Elacestrant in ERHER2- and ESR1 Mutations MBC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Safety of Elacestrant in the Treatment of Advanced Breast Cancer Patients With ERHER2- and ESR1-mutations Who Have Progressed on at Least One Line of Endocrine Therapy a Prospective Non-interventional Real-world Study
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a prospective non-interventional real-world study enrolling patients with advanced breast cancer who are ERHER2- and have ESR1- gene mutations collecting information on patients complaints physical examination laboratory tests imaging tests and adverse events to observe the safety of elacestrant treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None